Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
8.070 USD   +3.46%
12/01Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
PR
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The CompanyÔÇÖs alpha-4-beta-7 (╬▒4╬▓7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted ╬▒4╬▓7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.

Number of employees : 118 people.
Sales per Business
20202021Delta
Peptide-based Therapeutics28.63100%27.36100% -4.44%
USD in Million
Sales per region
20202021Delta
United States28.63100%27.36100% -4.44%
USD in Million
Managers
Name Title Age Since
Dinesh V. Patel, Dr. President, Chief Executive Officer & Director 64 2019
Asif Ali Chief Financial Officer & Executive Vice President 47 2022
Mark L. Smythe, Dr. Vice President-Technology - 2013
David Y. Liu, Dr. Chief Research & Development Strategy Officer 70 2022
Samuel R. Saks, Dr. Chief Medical Officer 66 2019
Paula OĺConnor, Dr. Senior Vice President-Clinical Development - -
Mohammad Masjedizadeh, Dr. Chief Technical officer & Executive VP - -
Arturo Molina, Dr. Chief Medical Officer 62 2022
Ashok Bhandari, Dr. Senior Director-Chemistry - -
Carter J. King Vice President-Business Development 49 2018
Members of the board
Name Title Age Since
Harold E. Selick, Dr. Chairman 66 2014
William D. Waddill Independent Director 64 2016
Lewis T. Williams, Dr. Independent Director 71 2017
Sarah B. Noonberg, Dr. Independent Director 53 2017
Bryan Giraudo Independent Director 45 2018
Sarah A. O'Dowd Independent Director 71 2020
Dinesh V. Patel, Dr. President, Chief Executive Officer & Director 64 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,198,411 48,482,405 98.5% 0 0.0% 98.5%
Shareholders
NameEquities%
SSgA Funds Management, Inc. 4,676,682 9.53%
RTW Investments LP 4,176,837 8.51%
Farallon Capital Management LLC 3,651,887 7.44%
Consonance Capital Management LP 3,446,874 7.02%
The Vanguard Group, Inc. 2,876,570 5.86%
Point72 Asset Management LP 2,537,993 5.17%
Johnson & Johnson Innovation JJDC, Inc. 2,449,183 4.99%
Bain Capital Life Sciences LP 2,260,572 4.61%
Fidelity Management & Research Co. LLC 1,991,339 4.06%
Deerfield Management Co. LP 1,172,943 2.39%
Company contact information
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160

Phone : +1.510.474.0170
Web : http://www.protagonist-inc.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Protagonist Therapeutics, Inc.
Connections : Protagonist Therapeutics, Inc.